A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
Jun Shao,Yunru Gu,Renhua Guo,Jiali Xu
DOI: https://doi.org/10.2147/dddt.s465238
IF: 4.3188
2024-06-26
Drug Design Development and Therapy
Abstract:Jun Shao, &ast Yunru Gu, &ast Renhua Guo, Jiali Xu Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Renhua Guo; Jiali Xu, Email ; Purpose: Activating mutations in epidermal growth factor receptor (EGFR) have been identified as key predictive biomarkers for the customized treatment with EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), aiding in improving patient response rates and survival. However, resistance challenges the efficacy of these treatments, with limited understanding of post-resistance therapeutic strategies. A deep understanding of the biology and resistance mechanisms of EGFR-mutant NSCLC is crucial for developing new treatment approaches. This study, through bibliometric analysis, summarizes the trends in research on resistance to EGFR-TKIs. Methods: Research papers on NSCLC with EGFR inhibitor resistance were collected from the Web of Science Core Collection (WoSCC). The analysis utilized bibliometric tools like CiteSpace, VOSviewer, and other platforms for comprehensive analysis and visualization of the outcomes. Results: The WoSCC database contains a total of 5866 documents on resistance to EGFR-TKIs treatment, including 4727 articles (93.48%) and 1139 reviews (6.52%), spanning 81 countries and regions, 4792 institutions, with the involvement of 23,594 authors. Since 2016, there has been a significant increase in publications in this field. China has the highest publication output, while the United States has the highest citation count for papers. Harvard University leads in terms of the number of publications. Among the top ten journals with the highest output, Clinical Cancer Research has the highest impact factor at 11.5, with 90% of the journals classified in Q1 or Q2. Rafael Rosell is one of the most influential authors in this field, ranking second in publication volume and fourth in citation count. Research on EGFR-TKIs resistance mainly focuses on genetic testing, resistance mechanisms, and post-resistance treatment strategies. Conclusion: This study provides researchers with a reliable basis and guidance for finding authoritative references, understanding research trends, and exploring potential directions. Keywords: NSCLC, EGFR mutation, EGFR-TKIs, bibliometric analysis, hot SPOTS Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, accounting for about 85% of cases. It primarily includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 1 The EGFR is a transmembrane glycoprotein with tyrosine kinase activity that plays a crucial role in physiological processes such as cell growth, proliferation, and differentiation through its phosphorylation. EGFR gene mutations are the most common driver gene mutations in NSCLC. Their primary mechanism of action is to regulate tumor cell proliferation, angiogenesis, and tumor cell invasion and metastasis by binding to extracellular ligands and undergoing homologous or heterologous dimerization. 2,3 Especially in the Chinese NSCLC population, the proportion of EGFR mutations is 28.2%, and in lung adenocarcinoma, this proportion rises to 50.2%. 4 The emergence of EGFR tyrosine kinase inhibitors (TKIs) has changed the standard treatment paradigm for patients with advanced EGFR mutation-positive NSCLC. TKIs have been evaluated and recommended as a first-line treatment option for patients with EGFR mutation-positive NSCLC by current treatment guidelines, including the National Comprehensive Cancer Network (NCCN). 5 Compared to traditional platinum-based chemotherapy, first- and second-generation EGFR-TKIs as first-line treatment for advanced NSCLC with classic EGFR mutations (deletions in EGFR exon 19 or L858R point mutations in exon 21) significantly improve median progression-free survival (mPFS) but not overall survival (OS). 6–8 Approximately 50%-60% of patients treated with first- or second-generation EGFR-TKIs as first-line therapy will develop secondary T790M resistance mutations. 9 Third-generation EGFR-TKIs can inhibit both EGFR-sensitive mutations and T790M resistance mutations, significantly increasing mPFS by about 10 months compared to first/second-generation EGFR-TKIs in patients with EGFR-sensitive mutations. 10–12 In the FLAURA study, Osimertinib achieved a statistically and clinically significant improvement in OS, extending it to 38.6 months (compared to 31.8 months in the control group, p=0.046). The results of the FLAURA2 study (comparing the efficacy and safety of Osimertinib in combination with chemotherapy versus -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal